

The General Court of the European Union agrees with PharmaMar on the ruling on Aplidin[®] (plitidepsin)

- **The Court has granted in full, PharmaMar's application to annul the Commission's Enforcement Decision, which refused to authorize the marketing of plitidepsin as a Multiple Myeloma treatment.**
- **The Company asked the Court to clarify the procedural guarantees and examination criteria, the verification of conflicts of interest by the experts appointed by the EMA and the correct analysis of the scientific evidence.**
- **The ADMYRE Phase III registration study achieved its primary objective of Progression Free Survival (PFS).**
- **The last report from the *Rapporteur* and *Co-Rapporteur* was positive.**

Madrid, October 28th, 2020. – PharmaMar (MSE:PHM) announced today that the General Court of the European Union has granted PharmaMar's application, in full, annulling the European Commission's decision to refuse to market Aplidin[®] (plitidepsin) for the treatment of patients with multiple myeloma, ordering the Commission to pay the costs.

On October 1st, 2018, PharmaMar filed a lawsuit with the General Court of the European Union against the European Commission, requesting the annulment of the Commission Implementing Decision, which refused to authorize the marketing of plitidepsin as a treatment for patients with multiple myeloma.

In this application, the Company requested the Court to clarify the procedural guarantees and examination criteria to be applied during a marketing authorization procedure before the European Medicines Agency (EMA). Specifically, the main grounds of the lawsuit related to the strict verification of conflicts of interest by the experts appointed by the EMA and the correct analysis of the scientific evidence presented by PharmaMar.

Today's decision by the European General Court confirms PharmaMar's long-standing position on the evaluation process of plitidepsin as a treatment for patients with multiple myeloma.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: Zepzelca™ (lurbinectedin, PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Álvaro Mateo - Communication Manager amateo@pharmamar.com Mobile: +34 650726009

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director

María Marín de la Plaza – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com